Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus

Gene Therapy

Volumn 6, Issue 1, 1999, Pages 63-73

  Schirrmacher, V ^a   Haas, C ^a   Bonifer, R ^a   Ahlert, T ^b   Gerhards, R ^c   Ertel, C ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b Laboratory Praxis Dr Ahlert   (Germany)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Chemokine induction; Hemagglutinin neuramindase

Indexed keywords

CANCER VACCINE; CHEMOKINE; CYTOKINE;

ARTICLE; CANCER; CELL INTERACTION; CELL PROLIFERATION; CELL SURFACE; GAMMA IRRADIATION; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LYMPHOCYTE; NEWCASTLE DISEASE PARAMYXOVIRUS; PRIORITY JOURNAL; VIRION; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION;

CANCER VACCINES; CELL ADHESION; CYTOKINES; GENE THERAPY; HUMANS; IMMUNOTHERAPY, ACTIVE; LEUKOCYTES; NEOPLASMS; NEWCASTLE DISEASE VIRUS; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

AMBYSTOMA TIGRINUM STEBBENSI VIRUS; AVES; NEWCASTLE DISEASE VIRUS; PARAMYXOVIRIDAE;

EID: 0032897339     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300787     Document Type: Article

References (45)

1. Alexander DJ, Allan HW. Newcastle disease virus pathotypes. Avian Pathol 1974; 3: 269-278.
2. Cassel WA, Garret RE. Newcastle disease virus as an antineoplastic agent. Cancer 1965; 7: 863-868.
3. Ito Y, Nagai Y, Maeno K. Interferon induction in mice spleen cells and mouse fibroblasts (L cells) stimulated by various strains of Newcastle disease virus. J Gen Virol 1982; 62: 349-352.
4. Lorence RM, Rood PA, Kelly KW. Newcastle disease virus as an antineoplastic agent: induction of tumor necrosis factor-α and augmentation of its cytotoxicity. J Natl Cancer Inst 1988; 80: 1305-1312.
5. Reichard KW et al. Newcastle disease virus selectively kills human cancer cells. J Surg Res 1991; 52: 448-453.
6. Zorn U et al. Induction of cytokines and cytotoxicity against tumor cells by Newcastle disease virus. Cancer Biother 1994; 9: 225-234.
7. Kenney S, Pagano JS. Editorial. Viruses as oncolytic agents: a new age of 'therapeutic' viruses? J Natl Cancer Inst 1994; 86: 1185-1186.
8. Svet-Moldavsky GJ. Tumor-induced skin heterogenization. II. Virus causing the phenomenon. J Natl Cancer Inst 1970; 45: 475-484.
9. Austin FC, Boone CW. Virus augmentation of the antigenicity of cell extracts. Adv Cancer Res 1979; 30: 301-345.
10. Cassel WA, Murray DR, Phillips HS. A phase 2 study on the postsurgical management of stage 2 malignant melanoma with a Newcastle disease virus oncolysate. Cancer 1983; 52: 856-860.
11. Cassel WA, Murray DR. A ten-year follow-up on stage II malignant melanoma patients treated postsurgically with Newcastle disease virus oncolysate. Med Oncol Tumor Pharmacother 1992; 9: 169-171.
12. Sinkovics JG, Papadopoulos NE, Plager C. Viral oncolysate for the immunotherapy of human tumors. In: Yohn DS, Blakeslee JR (eds). Advances in Comparative Leukemia Research: International Symposium for Comparative Research on Leukemia and Related Diseases, 10th edn. Elsevier: North Holland, New York, 1982, pp 613-615.
13. Heicappell R et al. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 1986; 37: 569-577.
14. Schirrmacher V et al. Successful application of non-oncogenic viruses for antimetastatic cancer immunotherapy. Cancer Rev 1986; 5: 19-49.
15. Liebrich W et al. In vitro and clinical characterization of a Newcastle disease virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 1991; 27: 703-710.
16. Schirrmacher V, von Hoegen P. Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res 1993; 2: 183-196.
17. Kobayashi H. Viral xenogenization of intact tumor cells. Adv Cancer Res 1997; 30: 279-299.
18. Peters LC, Hanna MG Jr. Active specific immunotherapy of established micro-metastases: effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 1980; 64: 1521-1525.
19. Schirrmacher V et al. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. IV. Antigenic differences between the parental tumor line and its metastasizing variant. Int J Cancer 1979; 23: 245-252.
20. Bosslet K, Schirrmacher V, Shantz G. Tumor metastases and cell-mediated immunity in a model system in DBA/2 mice. VI. Similar specificity patterns of protective anti-tumor immunity in vivo and of cytolytic T cells in vitro. Int J Cancer 1979; 24: 303-313.
21. Schirrmacher V, Schild HJ, Gückel B, von Hoegen P. Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and class II restricted tumor antigens. Immunol Cell Biol 1992; 71: 311-326.
22. Schirrmacher V, Heicappell R. Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. II. Establishment of specific systemic anti-tumor immunity. Clin Exp Met 1987; 5: 147-156.
23. Schirrmacher V, Haas C, Bonifer R, Ertel C. Virus potentiation of tumor vaccine T-cell stimulatory capacity requires cell surface binding but not infection. Clin Cancer Res 1997; 3: 1135-1148.
24. Kingsbury DW. Paramyxoviridae and their replication. In: Fields BN, Knipe DM (eds). Virology, 2nd edn. Raven Press: New York, 1990, pp 945-962.
25. Garten W et al. Mutational changes of the protease susceptibility of glycoprotein F of Newcastle disease virus: effects on pathogenicity. J Gen Virol 1980; 50: 135-147.
26. Lorence RM et al. Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 1994; 86: 1228-1233.
27. Csatary LK et al. Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 1993; 17: 619-627.
28. Von Hoegen P, Weber E, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus: augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur J Immunol 1988; 18: 1159-1166.
29. Von Hoegen P, Zawatzky R, Schirrmacher V. Modification of tumor cells by a low dose of Newcastle disease virus. III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon-α, β. Cell Immunol 1990; 126: 80-90.
30. Ertel C et al. Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur J Immunol 1993; 23: 2592-2596.
31. Jurianz K et al. Adhesive function of Newcastle disease virus hemagglutinin in tumor-host interaction. Int J Oncol 1995; 7: 539-545.
32. Ahlert T, Schirrmacher V. Isolation of a human melanoma adapted Newcastle disease virus mutant with highly selective replication patterns. Cancer Res 1990; 50: 5962-5968.
33. Schirrmacher V et al. Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. In: Schirrmacher V, Schwartz-Albiez R (eds). Cancer Metastasis. Springer Verlag: Berlin, Heidelberg, New York, 1989, pp 157-170.
34. 2b. Int J Oncol 1995; 6: 947-954.
35. Bohle W et al. Postoperative active specific immunization in colorectal cancer patients with virus-modified autologous tumor cell vaccine: first clinical results with tumor cell vaccines modified with live but avirulent Newcastle disease virus. Cancer 1990; 66: 1517-1523.
36. Lokuta MA et al. Mechanisms of murine RANTES chemokine gene induction by Newcastle disease virus. J Biol Chem 1996; 271: 13731-13738.
37. Schirrmacher V, Griesbach A, Zangemeister U. γ-Irradiated viable tumor cells as whole cell vaccines can stimulate in situ syngeneic anti-tumor CTL and DTH reactivity while tumor cell lysates elicit only DTH reactivity. Vaccine Res 1994; 3: 31-48.
38. Ockert D et al. Newcastle disease virus infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma. Clin Cancer Res 1996; 2: 21-28.
39. Schlag P et al. Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer: first evaluation of clinical response of a phase II trial. Cancer Immunol Immunother 1992; 35: 325-330.
40. Kirchner HH, Anton P, Atzpodien J. Adjuvant treatment of locally advanced renal cancer with autologous virus-modified tumor vaccines. World J Urol 1995; 13: 171-173.
41. Ahlert T et al. Tumor cell number and viability as quality and efficacy parameters of autologous virus modified cancer vaccines. J Clin Oncol 1997; 15: 1354-1366.
42. Hirst KG. The agglutination of rat cells by allantoic fluid of chick embryos infected with influenca virus. Science 1941; 94: 22-25.
43. Long L et al. Monoclonal antibodies to hemagglutinin-neuraminidase and fusion glycoproteins of Newcastle disease virus: relationship between glycosylation and reactivity. J Virol 1986; 57: 1198-1202.
44. Iorio RM, Bratt MA. Monoclonal antibodies as functional probes of the HN glycoprotein of Newcastle disease virus: antigenic separation of the hemagglutinin and neuraminidase sites. J Immunol 1984; 133: 2215-2219.
45. Haas C et al. Bispecific antibodies increase T cell stimulatory capacity in vitro of human autologous virus modified tumor vaccine. Clin Cancer Res 1998; 4: 721-730.